Alpine Woods Capital Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-8,000
Closed -$495K 206
2022
Q3
$495K Buy
8,000
+3,000
+60% +$210K 0.07% 148
2022
Q2
$399K Hold
5,000
0.05% 160
2022
Q1
$526K Hold
5,000
0.06% 164
2021
Q4
$539K Buy
5,000
+2,000
+67% +$218K 0.05% 169
2021
Q3
$329K Hold
3,000
0.04% 201
2021
Q2
$281K Hold
3,000
0.03% 215
2021
Q1
$276K Buy
+3,000
New +$253K 0.03% 215

Other funds holding HZNP

Alpine Woods Capital Investors's HZNP Position: Q4 2022 in Review

Alpine Woods Capital Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 8,000 shares — an estimated $495K sold.

Alpine Woods Capital Investors first reported a position in HZNP in Q1 2021 and held it in 7 quarters. The position peaked at $539K in Q4 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Alpine Woods Capital Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 8,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $495K.
  • Alpine Woods Capital Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 7 quarters.
  • Alpine Woods Capital Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $539K in Q4 2021.
  • 615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2022, filed 8 Feb 2023.